Ali Taher

Summary

Affiliation: American University of Beirut
Country: Lebanon

Publications

  1. ncbi request reprint Thalassemia intermedia: revisited
    Ali Taher
    Department of Internal Medicine, Hematology Oncology Division, American University of Beirut Medical Center, Beirut 1107 2020, Lebanon
    Blood Cells Mol Dis 37:12-20. 2006
  2. pmc Update on the use of deferasirox in the management of iron overload
    Ali Taher
    American University of Beirut, Beirut, Lebanon
    Ther Clin Risk Manag 5:857-68. 2009
  3. pmc Thalassaemia intermedia: an update
    Ali T Taher
    Department of Internal Medicine, Hematology Oncology Division, American University of Beirut Medical Centre, Beirut, Lebanon
    Mediterr J Hematol Infect Dis 1:e2009004. 2009
  4. pmc Thalassemia and venous thromboembolism
    Julien Succar
    Department of Internal Medicine, Hematology Oncology Division, American University of Beirut Medical Centre, Beirut, Lebanon
    Mediterr J Hematol Infect Dis 3:e2011025. 2011
  5. pmc Treating iron overload in patients with non-transfusion-dependent thalassemia
    Ali T Taher
    Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
    Am J Hematol 88:409-15. 2013
  6. pmc Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study
    Ali T Taher
    American University of Beirut, Beirut, Lebanon
    Ann Hematol 92:1485-93. 2013
  7. pmc Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients
    Ali T Taher
    Hematology and Oncology, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
    Am J Hematol 88:503-6. 2013
  8. doi request reprint Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study
    Ali T Taher
    American University of Beirut, Beirut, Lebanon
    Blood 120:970-7. 2012
  9. doi request reprint Mechanisms of renal disease in β-thalassemia
    Khaled M Musallam
    Department of Medicine and Medical Specialties, IRCCS Cà Granda Foundation Maggiore Policlinico Hospital, Milan, Italy
    J Am Soc Nephrol 23:1299-302. 2012
  10. doi request reprint Contemporary approaches to treatment of beta-thalassemia intermedia
    Ali T Taher
    American University of Beirut Medical Center, Beirut, Lebanon
    Blood Rev 26:S24-7. 2012

Collaborators

Detail Information

Publications123 found, 100 shown here

  1. ncbi request reprint Thalassemia intermedia: revisited
    Ali Taher
    Department of Internal Medicine, Hematology Oncology Division, American University of Beirut Medical Center, Beirut 1107 2020, Lebanon
    Blood Cells Mol Dis 37:12-20. 2006
    ..Here, we review the major clinical complications in thalassemia intermedia and suggest some therapeutic strategies based on retrospective clinical observations...
  2. pmc Update on the use of deferasirox in the management of iron overload
    Ali Taher
    American University of Beirut, Beirut, Lebanon
    Ther Clin Risk Manag 5:857-68. 2009
    ..The availability of this effective and generally well tolerated oral therapy represents a significant advance in the management of transfusional iron overload...
  3. pmc Thalassaemia intermedia: an update
    Ali T Taher
    Department of Internal Medicine, Hematology Oncology Division, American University of Beirut Medical Centre, Beirut, Lebanon
    Mediterr J Hematol Infect Dis 1:e2009004. 2009
    ..However, at present, there are no clear guidelines for an orchestrated optimal treatment plan...
  4. pmc Thalassemia and venous thromboembolism
    Julien Succar
    Department of Internal Medicine, Hematology Oncology Division, American University of Beirut Medical Centre, Beirut, Lebanon
    Mediterr J Hematol Infect Dis 3:e2011025. 2011
    ..Clinical experience and available clues on optimal management are also discussed...
  5. pmc Treating iron overload in patients with non-transfusion-dependent thalassemia
    Ali T Taher
    Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
    Am J Hematol 88:409-15. 2013
    ....
  6. pmc Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study
    Ali T Taher
    American University of Beirut, Beirut, Lebanon
    Ann Hematol 92:1485-93. 2013
    ..Deferasirox progressively decreases iron overload over 2 years in NTDT patients with both low and high LIC. Safety profile of deferasirox over 2 years was consistent with that in the core study. ..
  7. pmc Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients
    Ali T Taher
    Hematology and Oncology, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
    Am J Hematol 88:503-6. 2013
    ..5-≤12.5 mg/kg/day and >0-<7.5 mg/kg/day subgroups, demonstrating a dose-response efficacy. LIC reduction across patient subgroups was generally consistent with the primary efficacy analysis with a similar safety profile...
  8. doi request reprint Deferasirox reduces iron overload significantly in nontransfusion-dependent thalassemia: 1-year results from a prospective, randomized, double-blind, placebo-controlled study
    Ali T Taher
    American University of Beirut, Beirut, Lebanon
    Blood 120:970-7. 2012
    ..8%), and diarrhea (n = 6; 3.6%). This is the first randomized study showing that iron chelation with deferasirox significantly reduces iron overload in NTDT patients with a frequency of overall adverse events similar to placebo...
  9. doi request reprint Mechanisms of renal disease in β-thalassemia
    Khaled M Musallam
    Department of Medicine and Medical Specialties, IRCCS Cà Granda Foundation Maggiore Policlinico Hospital, Milan, Italy
    J Am Soc Nephrol 23:1299-302. 2012
    ..Nonprogressive increases in levels of serum creatinine have also been observed after exposure to some iron chelators. Longitudinal studies are needed to understand the true burden of renal dysfunction in patients with β-thalassemia...
  10. doi request reprint Contemporary approaches to treatment of beta-thalassemia intermedia
    Ali T Taher
    American University of Beirut Medical Center, Beirut, Lebanon
    Blood Rev 26:S24-7. 2012
    ..This review describes the current state of the art for medical management of TI, with particular focus on the roles of splenectomy, transfusion, and iron chelation therapy...
  11. pmc Burkitt's lymphoma of the colon and bronchi: three case reports
    Khaled M Musallam
    Department of Internal Medicine, Hematology Oncology Division, P, O, Box 11 0236, American University of Beirut Medical Center, Beirut, Lebanon
    Cases J 1:15. 2008
    ..abstract:..
  12. pmc Solitary mediastinal lymph node metastasis in rectosigmoid carcinoma: a case report
    Khaled M Musallam
    Department of Internal Medicine, Hematology Oncology Division, American University of Beirut Medical Center, Beirut, Lebanon
    Cases J 1:69. 2008
    ..abstract:..
  13. doi request reprint Thalassemia and hypercoagulability
    Ali T Taher
    Hematology Oncology Division, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
    Blood Rev 22:283-92. 2008
    ..We also discuss the recommendations for thrombosis prophylaxis in these patients...
  14. ncbi request reprint Ocular findings among thalassemia patients
    Ali Taher
    Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
    Am J Ophthalmol 142:704-5. 2006
    ..The study aims at studying the ophthalmologic status in a group of thalassemia patients...
  15. doi request reprint Asymptomatic brain magnetic resonance imaging abnormalities in splenectomized adults with thalassemia intermedia
    A T Taher
    Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
    J Thromb Haemost 8:54-9. 2010
    ..Brain involvement has not been widely studied in TI, although limited reports confirm a low incidence of overt stroke and high incidence of silent brain infarcts...
  16. pmc Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload
    Ali Taher
    Department of Internal Medicine, Haematology Oncology Division, American University of Beirut, Medical Centre, Beirut, Lebanon
    Br J Haematol 147:752-9. 2009
    ..This has important implications for patients who are heavily transfused and may require higher doses to reduce body iron burden...
  17. doi request reprint Iron overload: consequences, assessment, and monitoring
    Ali T Taher
    Department of Internal Medicine, Hematology Oncology Division, American University of Beirut Medical Center, Beirut, Lebanon
    Hemoglobin 33:S46-57. 2009
    ..Optimal iron overload assessment and monitoring is a key element in the development of improved strategies of iron chelation therapy that can be tailored to meet the patient's specific needs...
  18. ncbi request reprint Safety and effectiveness of 100 mg/kg/day deferiprone in patients with thalassemia major: a two-year study
    Ali Taher
    American University of Beirut Medical Center, Beirut, Lebanon
    Acta Haematol 114:146-9. 2005
    ..05). Liver iron levels at the end of the 2-year study ranged from 1.0 to 30.9 mg/g dry weight, 3 of the patients having levels above 15 mg/g...
  19. doi request reprint Levels of non-transferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia
    Ali Taher
    Department of Internal Medicine, Haematology Oncology Division, American University of Beirut Medical Centre, Beirut, Lebanon
    Br J Haematol 146:569-72. 2009
    ..36; P = 0.002) and serum ferritin (Pearson correlation 0.421; P < 0.0001); with higher levels observed in splenectomised patients. NTBI assessment has potential as a simple reliable approach to determining iron status in TI...
  20. ncbi request reprint Iron overload in thalassemia and sickle cell disease
    A Taher
    Hematology and Oncology, American University of Beirut Medical Center, Beirut, Lebanon
    Semin Hematol 42:S5-9. 2005
  21. doi request reprint Effects of divalproex sodium on hemoglobin level
    Ali T Taher
    Department of Internal Medicine, Division of Hematology Oncology, American University of Beirut Medical Center, Beirut, Lebanon
    Blood Cells Mol Dis 43:49-52. 2009
    ..Hb increase was evident in 47.0% of values. A clinically relevant increase in Hb (>0.5 g/dL) occurred in 23.9% of values. VPA is associated with a change in total Hb level that correlates inversely with baseline Hb levels...
  22. pmc Efficacy and safety of deferasirox, an oral iron chelator, in heavily iron-overloaded patients with beta-thalassaemia: the ESCALATOR study
    Ali Taher
    Department of Internal Medicine, Hematology, Oncology Division, American University of Beirut Medical Center, Beirut, Lebanon
    Eur J Haematol 82:458-65. 2009
    ..Phase II/III studies have shown that oral deferasirox 20-30 mg/kg/d reduces iron burden, depending on transfusional iron intake...
  23. doi request reprint The hypercoagulable state in thalassemia intermedia
    Ali T Taher
    Department of Internal Medicine, Hematology Oncology Division, American University of Beirut Medical Center, Beirut, Lebanon
    Hemoglobin 33:S160-9. 2009
    ..Recommendations for thrombosis prophylaxis in these patients are also discussed...
  24. ncbi request reprint Extramedullary hematopoiesis in a patient with beta-thalassemia intermedia manifesting as symptomatic pleural effusion
    A Taher
    Division of Hematology Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Lebanon
    Hemoglobin 25:363-8. 2001
    ..The pleural effusion was controlled by pleurodesis using tetracycline. We review the literature on this uncommon complication of beta-thalassemia intermedia and discuss the options for diagnosis and treatment...
  25. ncbi request reprint Comparison between deferoxamine and deferiprone (L1) in iron-loaded thalassemia patients
    A Taher
    The Chronic Care Centre, The American University of Beirut Medical Centre, Beirut, Lebanon
    Eur J Haematol 67:30-4. 2001
    ..However, the limitations of this treatment have stimulated the design of alternative orally active iron chelators...
  26. ncbi request reprint Pulmonary thromboembolism in beta-thalassemia intermedia: are we aware of this complication?
    Ali Taher
    Department of Internal Medicine, American University of Beirut Medical Center, Lebanon
    Hemoglobin 26:107-12. 2002
    ..A significant relationship between pulmonary thromboembolism and pulmonary hypertension in these patients was noted...
  27. ncbi request reprint Ticlopidine-induced aplastic anemia and quick recovery with G-CSF: case report and literature review
    A Taher
    Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
    Am J Hematol 63:90-3. 2000
    ..This risk should be seriously taken into consideration when prescribing ticlopidine. G-CSF may be helpful in the treatment of ticlopidine-induced aplastic anemia...
  28. pmc Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia
    Khaled M Musallam
    Department of Internal Medicine, Division of Hematology and Oncology, American University of Beirut Medical Center, Beirut, Lebanon
    Haematologica 96:1605-12. 2011
    ..This study evaluates whether iron overload in patients with β thalassemia intermedia is associated with morbidity...
  29. pmc Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: results from the ESCALATOR study
    Ali Taher
    American University of Beirut Medical Center, Beirut, Lebanon
    Eur J Haematol 87:349-54. 2011
    ..4 ± 5.2 mg/kg/d and significantly reducing LIC in patients with LIC ≥ 7 mg Fe/g dw at a mean dose of 25.7 ± 4.2 mg/kg/d, along with a manageable safety profile...
  30. pmc Importance of optimal dosing ≥ 30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia
    Ali Taher
    American University of Beirut Medical Center, Beirut, Lebanon
    Eur J Haematol 87:355-65. 2011
    ..44.3%). Doses ≥ 30 mg/kg/d were generally required because of high transfusional iron intake and high baseline serum ferritin levels, highlighting the importance of administering an adequate dose to achieve net negative iron balance...
  31. doi request reprint Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study
    Ali T Taher
    Department of Internal Medicine, Hematology Oncology Division, American University of Beirut Medical Center, Beirut, Lebanon
    Blood 115:1886-92. 2010
    ..This study provides evidence that calls for prospective evaluation of the roles of transfusion, iron chelation, and hydroxyurea therapy in TI patients...
  32. doi request reprint Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies
    Ali Taher
    Department of Internal Medicine, Haematology Oncology Division, American University of Beirut, Medical Centre, Beirut, Lebanon
    Br J Haematol 147:634-40. 2009
    ..Better understanding of the need to assess and treat iron overload in both transfused and non-transfused TI patients is clearly required...
  33. ncbi request reprint Improved treatment satisfaction and convenience with deferasirox in iron-overloaded patients with beta-Thalassemia: Results from the ESCALATOR Trial
    Ali Taher
    American University of Beirut, Lebanon
    Acta Haematol 123:220-5. 2010
    ..Patients reported greater satisfaction and convenience, and lower impact on daily activities, with deferasirox than with previous ICT. This may help improve adherence to lifelong ICT in iron-overloaded beta-thalassemia patients...
  34. doi request reprint The AVAIL ME study: a multinational survey of VTE risk and prophylaxis
    Ali T Taher
    Hematology Oncology Division, Department of Internal Medicine, American University of Beirut Medical Center, PO Box 11 0236, Riad El Solh, 1107 2020 Beirut, Lebanon
    J Thromb Thrombolysis 31:47-56. 2011
    ..16 was found between eligibility for VTE prophylaxis on one hand and its application in practice (P < 0.001). Risk factors for VTE and eligibility for VTE prophylaxis are common, but VTE prophylaxis and guidelines application are low...
  35. doi request reprint Optimal management of β thalassaemia intermedia
    Ali T Taher
    Department of Internal Medicine, Division of Haematology and Oncology, American University of Beirut Medical Centre, Riad El Solh 1107 2020, Beirut, Lebanon
    Br J Haematol 152:512-23. 2011
    ..Until solid evidence-based guidelines are available, individualised treatment should be entertained...
  36. doi request reprint Frequency of triple mutations involving factor V, prothrombin, and methylenetetrahydrofolate reductase genes among patients referred for molecular thrombophilia workup in a tertiary care center in Lebanon
    Rouba Hoteit
    Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon
    Genet Test Mol Biomarkers 16:223-5. 2012
    ....
  37. doi request reprint Relation between iron-overload indices, cardiac echo-Doppler, and biochemical markers in thalassemia intermedia
    Hussain Isma'eel
    Department of Internal Medicine Hematology Oncology Division, American University of Beirut, Medical Center, Beirut, Lebanon
    Am J Cardiol 102:363-7. 2008
    ....
  38. ncbi request reprint A clinical phase II study of cisplatinum and vinorelbine (PVn) in advanced breast carcinoma (ABC)
    Ali Shamseddine
    Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
    Am J Clin Oncol 28:393-8. 2005
    ..This report is a pilot study assessing the antitumor efficacy and safety of this regimen as first line therapy for advanced breast cancer patients...
  39. ncbi request reprint Beta-thalassemia intermedia: an overview
    Fuad El Rassi
    Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
    Pediatr Ann 37:322-8. 2008
  40. doi request reprint Pharmacogenomics variation in drug metabolizing enzymes and transporters in relation to docetaxel toxicity in Lebanese breast cancer patients: paving the way for OMICs in low and middle income countries
    Zainab Awada
    Department of Pharmacology and Toxicology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
    OMICS 17:353-67. 2013
    ....
  41. ncbi request reprint Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran
    Ali Taher
    Internal Medicine, American University of Beirut, Beirut, Lebanon
    Thromb Haemost 96:488-91. 2006
    ..Due to the increased risk of thromboembolic events, the rationale for splenectomy should perhaps be re-assessed and the role of transfusion therapy for the prophylaxis of thrombosis, among other complications, be evaluated prospectively...
  42. doi request reprint Genetic polymorphisms of CYP2E1, GST, and NAT2 enzymes are not associated with risk of breast cancer in a sample of Lebanese women
    Nathalie K Zgheib
    Department of Pharmacology and Toxicology, Faculty of Medicine, American University of Beirut, Lebanon
    Mutat Res 747:40-7. 2013
    ..Further studies are needed to determine the genetic predisposition and gene-environment interactions of breast cancer in this population...
  43. ncbi request reprint Cisplatin and vinorelbine (PVn) for the treatment of advanced breast cancer: 10 years of experience
    Ali Shamseddine
    Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
    J Med Liban 52:126-30. 2004
    ..Our data will be compared with other groups using the same regimen for the management of advanced breast carcinoma...
  44. doi request reprint Absence of JAK2 V617F mutation in thalassemia intermedia patients
    Ali Taher
    Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
    Mol Biol Rep 36:1555-7. 2009
    ..The latter's V617F mutation does not seem to play a role in this hematologically important clinical entity...
  45. ncbi request reprint Comparison between desferrioxamine and combined therapy with desferrioxamine and deferiprone in iron overloaded thalassaemia patients
    Fadi H Mourad
    Department of Internal Medicine, The American University of Beirut Medical Centre, Beirut, Lebanon
    Br J Haematol 121:187-9. 2003
    ..Main side-effects were skin reactions (DFX alone), nausea and arthralgia (combined therapy). As chelation therapy, the combined protocol was as effective as DFX five times weekly...
  46. ncbi request reprint Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection
    Adlette Inati
    Chronic Care Center, American University of Beirut Medical Center, Beirut, Lebanon
    Br J Haematol 130:644-6. 2005
    ..05). Transfusion requirements rose by 34% in the combination arm (P=0.08). Peginterferon/ribavirin was effective in thalassaemics with HCV and moderate iron overload...
  47. ncbi request reprint Peripheral neuropathy in thalassaemia
    Raja A Sawaya
    Department of Internal Medicine, American University Medical Center, Beirut, Lebanon
    Ann Saudi Med 26:358-63. 2006
    ..The aim of the study was to document whether these patients suffer from a polyneuropathy and to determine any contributing factors for the development of neuropathy...
  48. ncbi request reprint Thrombotic thrombocytopenic purpura: 24 years of experience at the American University of Beirut Medical Center
    Ali Shamseddine
    Department of Internal Medicine, American University of Beirut Medical Center, Lebanon
    J Clin Apher 19:119-24. 2004
    ..3%. TTP remains a fatal disease. A high index of suspicion should, therefore, always be present. Treatment options should be further developed and patients should directly be referred to tertiary care centers...
  49. doi request reprint Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people
    Maria O Esmerian
    Pharmacology and Therapeutics, Faculty of Medicine, American University of Beirut, Riad El Solh, Beirut 1107 2020, Lebanon
    J Clin Pharmacol 51:1418-28. 2011
    ....
  50. doi request reprint Concomitant occurrence of kimura disease and mycosis fungoides in a Lebanese woman: significance and response to rituximab
    Samer Ghosn
    Department of Dermatology, American University of Beirut Medical Center, Beirut, Lebanon
    Am J Dermatopathol 31:814-8. 2009
    ..Although the KD lesions persisted, they became softer and less nodular. As for the MF lesions, they flared transiently and then exhibited a sustained improvement over a follow-up period of 1 year...
  51. ncbi request reprint Massive pulmonary embolism in a Lebanese patient doubly heterozygous for MTHFR and Factor V Leiden presenting with syncope and treated with tenecteplase
    Hussain Isma'eel
    American University of Beirut Medical Center, P O Box 11 0236 A19, Riad El Solh, 11072020, Beirut, Lebanon
    J Thromb Thrombolysis 21:179-84. 2006
  52. ncbi request reprint Underutilization of venous thromboemoblism prophylaxis in medical patients in a tertiary care center
    Ramy Masroujeh
    Department of Internal Medicine, American University of Beirut Medical Center, P O Box 11 0236, Riad El Solh, Beirut, 1107 2020, Lebanon
    J Thromb Thrombolysis 26:138-41. 2008
    ..This study aims at assessing how much house-staff in a tertiary care setting are implementing these new recommendations in the hope that through quantitative analysis of the deficiency we would be able to identify areas of weakness...
  53. doi request reprint JAK2 V617F gene mutation in the laboratory work-up of myeloproliferative disorders: experience of a major referral center in Lebanon
    Rami A R Mahfouz
    Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon
    Genet Test Mol Biomarkers 15:263-5. 2011
    ..This report is the first of its kind from Lebanon that analyzes the distribution of this mutation among a series of referred cases to a major tertiary referral center...
  54. ncbi request reprint Hypertransfusion: a successful method of treatment in thalassemia intermedia patients with spinal cord compression secondary to extramedullary hematopoiesis
    Aref Chehal
    American University of Beirut Medical Center, Beirut, Lebanon
    Spine (Phila Pa 1976) 28:E245-9. 2003
    ..Spinal cord compression may result in the rare cases wherein the hematopoietic develops intraspinally. Treatment of such conditions still is controversial...
  55. ncbi request reprint Transfusion-associated GVHD: 10 years' experience at the American University of Beirut-Medical Center
    Elie Aoun
    Department of Internal Medicine, American Universitty of Beirut Medical Center, Beirut, Lebanon
    Transfusion 43:1672-6. 2003
    ..Although rare, transfusion-associated GVHD (TA-GVHD) is a fatal complication of blood transfusion in which active lymphocytes from the donor attack and destroy recipient organs and tissues...
  56. ncbi request reprint Beta-globin gene cluster haplotypes and HbF levels are not the only modulators of sickle cell disease in Lebanon
    A Inati
    Hematology Unit, Chronic Care Center, Beirut, Lebanon
    Eur J Haematol 70:79-83. 2003
    ..In addition, the high levels of HbF in patients with CAR haplotypes did not seem to ameliorate the severity of symptoms, suggesting that genetic factors other than haplotypes are the major determinants of increased HbF levels in Lebanon...
  57. ncbi request reprint Five-year trial of deferiprone chelation therapy in thalassaemia major patients
    A Taher
    Department of Internal Medicine, American University of Beirut, Medical Center, Beirut, Lebanon
    Acta Haematol 112:179-83. 2004
    ..In a minority, higher doses of deferiprone or a combination with desferrioxamine would be needed to lower liver iron below 15 mg/g...
  58. ncbi request reprint A review of the off-label use of recombinant activated factor VII in a developing country tertiary care center
    Ramzi El Accaoui
    American University of Beirut Medical Center, Beirut, Lebanon
    Blood Coagul Fibrinolysis 17:647-50. 2006
    ..Although off-label use of rFVIIa at AUB MC was supported by published reports, and associated with few complications, guidelines are required to control use of this medication...
  59. doi request reprint Livedoid vasculopathy associated with sickle cell trait: significant improvement on aspirin treatment
    Jinane El Khoury
    Dermatology Department, American University of Beirut Medical Center, Beirut, Lebanon
    Int Wound J 9:344-7. 2012
    ..In this study, we describe, to the best of our knowledge, the first report of LV only associated with sickle cell trait with significant improvement on aspirin...
  60. doi request reprint The hematologic manifestations of the antiphospholipid syndrome
    Imad Uthman
    Division of Rheumatology, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
    Blood Rev 22:187-94. 2008
    ..A high index of suspicion is needed for the early recognition and treatment of these conditions...
  61. ncbi request reprint Sickle cell disease: new insights into pathophysiology and treatment
    Adlette Inati
    Rafik Hariri University Hospital, Division of Pediatric Hematology and Oncology, Beirut, Lebanon
    Pediatr Ann 37:311-21. 2008
  62. ncbi request reprint Hb H disease and multiple myeloma
    Ihab Elhajj
    Department of Internal Medicine, Division of Hematology Oncology, American University of Beirut, Beirut, Lebanon
    Hemoglobin 28:79-82. 2004
  63. ncbi request reprint Cisplatin plus vinorelbine (PVn) as a salvage regimen for refractory breast cancer
    Aref Chehal
    Division of Hematology Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Box 113 6044, Beirut 1107 2802, Lebanon
    Breast 13:421-4. 2004
    ..In this paper, we report on a patient with advanced breast cancer who attained complete response of 14 months duration to a cisplatin/vinorelbine combination after progression during treatment with paclitaxel and doxorubicin...
  64. ncbi request reprint Anticardiolipin antibodies in patients with retinal vein occlusion and no risk factors: a prospective study
    Ziad F Bashshur
    Department of Ophthalmology, American University of Beirut Medical Center, Beirut, Lebanon
    Retina 23:486-90. 2003
    ..The purpose of this study was to look at the prevalence of these antibodies in patients with RVO disease and no conventional risk factors. We specifically examined how APAs may affect the course of this disease...
  65. ncbi request reprint Hughes syndrome associated with varicella infection
    I Uthman
    American University of Beirut, Medical Center, Lebanon
    Rheumatol Int 20:167-8. 2001
    ..IgM and IgG anticardiolipin (aCL) were both positive upon admission. The IgM aCL antibodies were still positive 6 weeks later, which suggests their role as a predisposing factor of deep vein thrombosis...
  66. ncbi request reprint Beta-thalassemia mutations and haplotype analysis in Lebanon
    L Zahed
    Department of Pathology and Laboratory Medicine, American University of Beirut, Lebanon
    Hemoglobin 24:269-76. 2000
    ..The five most common mutations were each found on two different haplotypes, and most linkages were as previously reported in other Mediterranean populations, with a few exceptions, also showing some clustering...
  67. ncbi request reprint Campylobacter fetus pericarditis in a patient with beta-thalassemia: case report and review of the literature
    S S Kanj
    Division of Infectious Diseases, Department of Internal Medicine, American University of Beirut, PO Box 113 6044, Beirut, Lebanon
    Clin Microbiol Infect 7:510-3. 2001
    ..Pericarditis due to C. fetus has rarely been reported. A high index of suspicion is essential to recognise this organism, because of its special microbiological characteristics...
  68. ncbi request reprint A comparison between prophylaxis and on demand treatment for severe haemophilia
    R Khoriaty
    Khatharine Dormandy Haemophilia Centre, Royal Free Hampstead NHS Trust, London, UK
    Clin Lab Haematol 27:320-3. 2005
    ..4). This suggests that prophylaxis reduces the risk of arthropathies, the number of future hospital visits and orthopaedic surgeries, and is thus the optimal modality of treatment for patients with severe haemophilia...
  69. ncbi request reprint Hepatitis-C-virus genotypes and hepatitis-G-virus infection in Lebanese thalassaemics
    S Ramia
    Faculty of Health Sciences, American University of Beirut, Lebanon
    Ann Trop Med Parasitol 96:197-202. 2002
    ..This and stringent infection-control measures are necessary steps to limit the spread of HBV, HCV and perhaps HGV to thalassaemics...
  70. doi request reprint The untold story of Dabigatran etexilate: alveolar hemorrhage in an elderly patient with interstitial pulmonary fibrosis
    Ahmad Husari
    Department of Internal Medicine, American University of Beirut Medical Center, P O Box 11 0236, Riad El Solh, Beirut, 110 72020, Lebanon
    J Thromb Thrombolysis 35:81-2. 2013
    ..The patient's medical condition improved and was subsequently discharged home. Our case illustrates the failure of current literature to predict the isolated bronchoalveolar bleed secondary to Dabigatran therapy...
  71. doi request reprint Successful treatment of refractory skin manifestations of systemic lupus erythematosus with rituximab: report of a case
    Imad Uthman
    Department of Dermatology, American University of Beirut Medical Center, Beirut, Lebanon
    Dermatology 216:257-9. 2008
  72. ncbi request reprint Successful treatment of B-cell prolymphocytic leukemia with monoclonal anti-CD20 antibody
    Yasser Abou Mourad
    Department of Internal Medicine, American University of Beirut Medical Center, Box 113 6044, 1107 2802, Beirut, Lebanon
    Ann Hematol 83:319-21. 2004
    ..She remains in complete remission 8 months following the discontinuation of treatment. This is the second reported case of successful treatment of B-cell PLL with rituximab...
  73. ncbi request reprint Thrombotic thrombocytopenic purpura and pregnancy: report of four cases and literature review
    Ali Shamseddine
    Division of Hematology Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
    J Clin Apher 19:5-10. 2004
    ..Review of the previously reported cases of pregnancy-related TTP and the current treatment options for this rare condition are discussed also...
  74. ncbi request reprint The role of therapeutic plasma exchange in the catastrophic antiphospholipid syndrome
    Imad Uthman
    Department of Internal Medicine, Division of Rheumatology, American University of Beirut Medical Center AUBMC, Hamra Street, Beirut 1107 2802, Lebanon
    Transfus Apher Sci 33:11-7. 2005
    ..The use of this technique, along with anticoagulation and if needed pharmacological immunosuppression, should be considered for the acute management of patients who present with this life-threatening condition...
  75. doi request reprint High prevalence of MTHFR gene A1298C polymorphism in Lebanon
    Amira S Sabbagh
    Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon
    Genet Test 12:75-80. 2008
    ....
  76. ncbi request reprint Age distribution of breast cancer in Lebanon: increased percentages and age adjusted incidence rates of younger-aged groups at presentation
    Nagi S El Saghir
    Department of Internal Medicine, American University of Beirut, Beirut, Lebanon
    J Med Liban 50:3-9. 2002
    ..Earlier studies showed that it sees about one third of all cancer cases in Lebanon...
  77. ncbi request reprint Moyamoya syndrome with intraventricular hemorrhage in an adult with factor V Leiden mutation
    Rosette Jabbour
    Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
    Arch Neurol 62:1144-6. 2005
    ..To report a case of proximal occlusion of 2 major cerebral vessels associated with moyamoya network circulation that manifested by spontaneous intraventricular hemorrhage...
  78. ncbi request reprint Report of a rare co-incidence of congenital factor V deficiency and thalassemia intermedia in a family
    Yasser Abou Mourad
    Division of Hematology Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
    Ann Saudi Med 24:301-2. 2004
  79. ncbi request reprint Gaucher disease: different clinical manifestations associated with a rare mutation (R48W) in a Lebanese family
    Lara M El-Zahabi
    Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
    Mol Genet Metab 91:402-4. 2007
    ..Our patients' clinical course is described. We also review the English literature for patients with this rare mutation...
  80. ncbi request reprint Pregnancy outcome in women with prosthetic heart valves
    Anwar H Nassar
    Department of Obstetrics and Gynecology, American University of Beirut Medical Center, Lebanon
    Am J Obstet Gynecol 191:1009-13. 2004
    ..This study was undertaken to evaluate the risks and pregnancy outcome in women with prosthetic heart valves on different anticoagulent regimens...
  81. doi request reprint Current understanding in the management of sickle cell disease
    Adlette Inati
    Division of Pediatric Hematology Oncology, Rafik Hariri University Hospital, Beirut, Lebanon
    Hemoglobin 33:S107-15. 2009
    ..This article will highlight modern management of SCD and its impact on the lives of affected patients...
  82. doi request reprint The impact of inherited thrombophilia on surgery: a factor to consider before transplantation?
    Elias Kfoury
    Department of Surgery, American University of Beirut Medical School, Beirut, Lebanon
    Mol Biol Rep 36:1041-51. 2009
    ..This topic is gaining more and more importance for both surgeons and internists (especially Hematologists) and we, herein, present a general review of the published literature as an update on the subject...
  83. doi request reprint Challenges associated with prolonged survival of patients with thalassemia: transitioning from childhood to adulthood
    Khaled Musallam
    Faculty of Medicine, American University of Beirut Medical Center, Riad El Solh 1107 2020, Beirut, Lebanon
    Pediatrics 121:e1426-9. 2008
    ..These issues and our recommendations for handling them are discussed...
  84. doi request reprint Severe hemophagocytic syndrome developing after treatment initiation for disseminated Mycobacterium tuberculosis: case report and literature review
    Maher M Balkis
    Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
    Scand J Infect Dis 41:535-7. 2009
    ..Later, while on anti-tuberculous treatment, he developed pancytopenia and bone marrow aspirate showed large macrophages with increased phagocytosis of mature and immature blood elements typical of hemophagocytic syndrome...
  85. ncbi request reprint Deep venous thrombosis in a patient with Behçet's disease and homozygous prothrombin (factor II) G20210A mutation on oral contraceptive pills
    Imad Uthman
    Department of Internal Medicine, Faculty of Medicine, American University of Beirut Medical Center, 113 6044, Beirut, Lebanon
    Rheumatol Int 26:758-9. 2006
    ..Our case suggests that a thrombophilia work-up may be warranted in BD patients, especially young women before they are prescribed oral contraceptives...
  86. ncbi request reprint Lupus anticoagulant, factor V Leiden, and methylenetetrahydrofolate reductase gene mutation in a lupus patient with cerebral venous thrombosis
    Imad Uthman
    Department of Internal Medicine, Faculty of Medicine, Medical Center, American University of Beirut, Beirut, Lebanon
    Clin Rheumatol 23:362-3. 2004
    ..The detection of such abnormalities may have major practical consequences for the long-term management of these patients to prevent further thrombotic episodes...
  87. ncbi request reprint Sickle cell disease: the Lebanese experience
    A Inati
    Division of Pediatric Hematology Oncology, Rafik Hariri University Hospital, Beirut, Lebanon
    Int J Lab Hematol 29:399-408. 2007
    ....
  88. ncbi request reprint Genetic heterogeneity of Beta thalassemia in Lebanon reflects historic and recent population migration
    N J Makhoul
    Department of Obstetrics and Gynecology, American University of Beirut, Beirut, Lebanon
    Ann Hum Genet 69:55-66. 2005
    ..This study provides information about the types and distribution of beta-thalassemia mutations within each religious group and geographic region, which is essential for the implementation of screening and prevention programs...
  89. ncbi request reprint Effect of oral iron chelation therapy with deferiprone (L1) on the psychosocial status of thalassaemia patients
    L Zahed
    Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Lebanon
    Haematologia (Budap) 31:333-9. 2002
    ..Evaluation of a larger sample of patients over a longer period of time is needed in order to confirm the favourable results obtained in this study...
  90. ncbi request reprint Survival and complications of beta-thalassemia in Lebanon: a decade's experience of centralized care
    K Charafeddine
    American University of Beirut Medical Center, Beirut, Lebanon
    Acta Haematol 120:112-6. 2008
    ..The introduction of new oral iron chelators and better iron overload quantitation methods will most likely modify this picture, and a follow-up study will examine their impact...
  91. ncbi request reprint Beta-thalassemia intermedia and non-Hodgkin's lymphoma
    Aref Chehal
    Department of Internal Medicine, American University of Beirut, Lebanon
    Hemoglobin 26:219-25. 2002
    ..On reviewing the literature, only four cases of thalassemia and lymphoma have been reported worldwide, thus making our case the fifth report of this rare combination of diseases...
  92. ncbi request reprint Novel mutation, L371V, causing multigenerational Gaucher disease in a Lebanese family
    A Shamseddine
    Department of Internal Medicine, Hematology Oncology Division, American University of Beirut, Lebanon
    Am J Med Genet A 125:257-60. 2004
    ..It is unknown whether L371V is a private mutation limited to this family, or will prove to be a common mutation within the Lebanese population...
  93. ncbi request reprint Sicklemia with multi-organ failure syndrome and thrombotic thrombocytopenic purpura
    Aref Chehal
    Division of Hematology Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Box 113 6044, Beirut 1107 2802, Lebanon
    Hemoglobin 26:345-51. 2002
    ..The dramatic response to therapy with plasma exchange, a treatment often effective in TTP, suggests a similarity in pathophysiology of micro-vascular occlusion and multi-organ failure in sickle cell disease...
  94. ncbi request reprint Endometrial metastasis from signet-ring breast carcinoma: case report
    A Chehal
    Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
    Eur J Gynaecol Oncol 23:563-4. 2002
    ..The patient presented with vaginal bleeding and was found to have wide spread metastasis. Endometrial metastasis in patients with signet-ring breast cancer usually denotes a poor prognosis...
  95. ncbi request reprint Genetic thrombophilia in patients with VTE in eastern Mediterranean located tertiary care center; is it time to change the algorithm for thrombophilia work up decision making?
    H Isma'eel
    American University of Beirut Medical Center, Beirut, Lebanon
    J Thromb Thrombolysis 21:267-70. 2006
    ..Therefore the aim of this study was to describe the experience of a tertiary care center in thrombophilia work up among patients diagnosed with VTE...
  96. ncbi request reprint IgM myeloma and Waldenstrom's macroglobulinemia: a distinct clinical feature, histology, immunophenotype, and chromosomal abnormality
    A Chehal
    Division of Hematology Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
    Clin Lab Haematol 25:187-90. 2003
    ..The clinical characteristics of a patient diagnosed with IgM myeloma, and his excellent response to treatment are reported here...
  97. ncbi request reprint Breast cancer in Lebanon. Increased age-adjusted incidence rates in younger-aged groups at presentation: implications for screening and for Arab-American ethnic groups
    N S El Saghir
    American University of Beirut Medical Center, Lebanon
    Ethn Dis 15:S1-11-2. 2005
  98. ncbi request reprint Idiopathic thrombocytopenic purpura and ovarian cancer
    A Chehal
    Division of Hematology Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
    Eur J Gynaecol Oncol 24:539-40. 2003
    ..We report a case of a 47-year-old woman diagnosed with ovarian cancer who presented with abdominal distention and thrombocytopenia. Her clinical course and the mechanisms of thrombocytopenia are discussed...
  99. ncbi request reprint Coexistence of lupus anticoagulant and acquired haemophilia in a patient with monoclonal gammopathy of unknown significance
    A Taher
    Department of Internal Medicine, Faculty of Medicine, American University of Beirut, Beirut, Lebanon
    Lupus 12:854-6. 2003
    ....
  100. ncbi request reprint Familial antiphospholipid antibodies and acquired circulating anticoagulants
    I Elhajj
    Department of Internal Medicine, American University of Beirut Medical Center, Beirut, Lebanon
    Lupus 13:812-4. 2004
    ....